Analyst Ratings For Alkermes Plc (NASDAQ:ALKS)
Today, Alkermes Plc (NASDAQ:ALKS) stock was downgraded by Credit Suisse Group from Outperform to Underperform with a price target of $31.00.
There are 5 Hold Ratings, 5 Buy Ratings, 2 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Alkermes Plc (NASDAQ:ALKS) is Hold with a consensus target price of $49.4167 per share, a potential 45.47% upside.
Some recent analyst ratings include
- 12/13/2018-Alkermes Plc (NASDAQ:ALKS) gets downgraded to Underperform by Credit Suisse Group with a price target of $31.00
- 11/12/2018-Alkermes Plc (NASDAQ:ALKS) has coverage initiated with a Market Perform rating and $36.00 price target
- 11/5/2018-Alkermes Plc (NASDAQ:ALKS) had its Neutral ➝ Neutral rating reiterated by Cantor Fitzgerald with a $41.00 price target
- 11/5/2018-Alkermes Plc (NASDAQ:ALKS) has coverage initiated with a Neutral ➝ Neutral rating and $40.00 price target
- 10/30/2018-Alkermes Plc (NASDAQ:ALKS) had its Buy rating reiterated by Cowen with a $58.00 price target
- On 12/3/2018 Paul J Mitchell, Director, sold 1,000 with an average share price of $36.45 per share and the total transaction amounting to $36,450.00.
- On 11/2/2018 Paul J Mitchell, Director, sold 1,000 with an average share price of $37.51 per share and the total transaction amounting to $37,510.00.
- On 10/1/2018 Paul J Mitchell, Director, sold 1,000 with an average share price of $42.42 per share and the total transaction amounting to $42,420.00.
- On 9/4/2018 Paul J Mitchell, Director, sold 1,000 with an average share price of $44.58 per share and the total transaction amounting to $44,580.00.
- On 8/1/2018 Paul J Mitchell, Director, sold 1,000 with an average share price of $43.68 per share and the total transaction amounting to $43,680.00.
- On 7/16/2018 Floyd E Bloom, Director, sold 20,000 with an average share price of $43.95 per share and the total transaction amounting to $879,000.00.
- On 7/3/2018 Paul J Mitchell, Director, sold 1,000 with an average share price of $41.86 per share and the total transaction amounting to $41,860.00.
About Alkermes Plc (NASDAQ:ALKS)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes. It is also developing Aripiprazole Lauroxil NanoCrystal Dispersion; ALKS 5461 for the treatment of depressive disorder; ALKS 3831 to treat schizophrenia; BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; and ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; development and license agreement with AstraZeneca plc; and license and collaboration agreement with Biogen MA Inc. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Recent Trading Activity for Alkermes Plc (NASDAQ:ALKS)
Shares of Alkermes Plc closed the previous trading session at 33,78 −1,72 4,83 % with 32.37 shares trading hands.
